CHEOY:OTCMKTS
Cochlear Ord ADR
44,72 $
arrow_downward
-0,07%(-0,030) 1 d.
15. okt., 16:00:00 GMT-4 · USD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: CHEOY…
Atvērt
44,61 $
Augsta
44,82 $
Zema
44,60 $
Tirgus kapitalizācija
8,56 mljrd.
Vid. apjoms
18,50 tūkst.
Apjoms
26,66 tūkst.
Augstākā 52 ned.
98,49 $
Zemākā 52 ned.
31,82 $
Beta
0,68
Apgrozībā esošās akcijas
130,80 milj.
Darbinieku skaits
5 tūkst.
Atvērt
44,61 $
Augsta
44,82 $
Zema
44,60 $
Tirgus kapitalizācija
8,56 mljrd.
Vid. apjoms
18,50 tūkst.
Apjoms
26,66 tūkst.
Augstākā 52 ned.
98,49 $
Zemākā 52 ned.
31,82 $
Beta
0,68
Apgrozībā esošās akcijas
130,80 milj.
Darbinieku skaits
5 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
ad-hoc-news.de
·
pirms 8 stundām
UBS keeps AUD 135.00 target for Cochlear stock
Simply Wall Street
·
pirms 9 stundām
Cochlear And 2 Australian Healthcare Stocks To Watch
PR Newswire
·
pirms 1 dienas
Cochlear Named #1 Most Trustworthy Healthcare Company In The World For 2026
Profils
Cochlear is a medical device company that designs, manufactures, and supplies the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant.
Based in Sydney, Cochlear was formed in 1981 as a subsidiary of Nucleus with finance from the Australian government to commercialise the implants pioneered by Dr. Graeme Clark, although the company later became separate. As of 2022, the company holds 50% of the cochlear implant market, with more than 250,000 people receiving one of Cochlear's implants as of 2015.
Cochlear was named Australia's most innovative company by the Intellectual Property Research Institute of Australia in 2002 and 2003, and one of the world's most innovative companies by Forbes in 2011. Wikipedia
Par “Cochlear Ord ADR”
ĢenerāldirektorsDig Howitt
Darbinieki5,4 tūkst.
Dibināšanas datums1981
Galvenais birojsSidneja, Jaundienvidvelsa, Austrālija
Sektors-
Tīmekļa vietnecochlear.com